Medium- and longer-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial

Markos Klonizakis1,2*, Anil Gumber1,2, Emma McIntosh1 and Leonie S. Brose3,4

Abstract

Background: Smoking is a major risk factor for cardiovascular disease and smoking cessation reduces excess risk. E-cigarettes are popular for smoking cessation but there is little evidence on their cardiovascular health effect. Our objective was to compare the medium- and longer-term cardiovascular effects in smokers attempting to quit smoking using e-cigarettes with or without nicotine or prescription nicotine replacement therapy (NRT).

Methods: This was a single-center, pragmatic three-arm randomized (1:1:1) controlled trial, which recruited adult smokers (≥ 10 cigarettes/day), who were willing to attempt to stop smoking with support (n = 248). Participants were randomized to receive behavioral support with either (a) e-cigarettes with 18 mg/ml nicotine, (b) e-cigarettes without nicotine, and (c) NRT. Flow-mediated dilation (%FMD) and peak cutaneous vascular conductance (CVCmax) responses to acetylcholine (ACh) and sodium nitroprusside (SNP), mean arterial pressure (MAP), and other outcomes were recorded at baseline, 3, and 6 months after stopping smoking. Data were analyzed using generalized estimating equations (GEE).

Results: At 3- and 6-month follow-up, %FMD showed an improvement over baseline in all three groups (e.g., p < 0.0001 at 6 months). Similarly, ACh, SNP, and MAP improved significantly over baseline in all groups both at 3 and 6 months (e.g., ACh: p = 0.004, at 6 months).

Conclusions: Smokers attempting to quit experienced positive cardiovascular impact after both a 3- and 6-month period. None of the groups (i.e., nicotine-containing and nicotine-free e-cigarettes or NRT) offered superior cardiovascular benefits to the others.

Trial registration: ClinicalTrials.gov NCT03061253. Registered on 17 February 2017.

Keywords: CVD, Smoking cessation, Vaping, Nicotine replacement therapy, Vascular function

Background

Smoking remains the second-leading mortality risk factor in the world [1], mainly due to cancer, lung disease, and cardiovascular disease (CVD). Smoking prevalence in the UK has declined substantially over the last decades to 14% in 2019 [2]. Nonetheless, smoking-caused deaths remain high (78,000 deaths in 2017 [3]), with smoking...
being the leading risk factor for loss of healthy life years [1].

Smoking is a major CVD risk factor. This is because it causes endothelial injury and dysfunction in both coronary and peripheral arteries and an increased risk of thrombosis. Smoking also produces a chronic inflammatory state that contributes to atherogenic disease processes and elevated levels of biomarkers of inflammation [4]. The negative effects upon cardiovascular function are not limited to smokers; passive smoking increases heart disease death-risk by almost 30% [5].

Thankfully, smoking cessation offers CVD risk-reduction benefits, which increase as time since cessation increases [6]. A combination of behavioral support and pharmacological interventions, particularly using two forms of nicotine replacement therapy (NRT) or varenicline, is the most effective approach to smoking cessation [7–9]. However, even the best methods have high relapse rates of over 75% within a year [10]. In the UK, stop-smoking services offer behavioral support and medication; however, the number of services has been reduced year on year [11].

Vaping products or electronic cigarettes (e-cigarettes) have been the most popular choice of support for smoking cessation in England, and by 2020 were being used by 27% of smokers making a cessation attempt [12], compared with for example 18% who used nicotine replacement therapy (NRT).

A recent Cochrane review concluded cessation was higher with nicotine-containing e-cigarettes than with NRT, nicotine-free e-cigarettes, or behavioral support [13]. Population-level survey data show that cessation attempts with the use of an e-cigarette had increased odds of success (OR = 1.95, 95% confidence interval (CI): 1.69–2.24) compared with those using any other support [14]. Per year, an additional 50,000–70,000 smokers in England have stopped smoking successfully, who without e-cigarettes would have continued smoking [15]. Routine monitoring data from stop-smoking services indicate that clients using e-cigarettes in their supported quit attempt are at least as likely to stop smoking as those using prescription medication [3, 12].

Nevertheless, evidence on the effect of e-cigarettes on cardiovascular health remains limited [16, 17]. Systematic reviews of e-cigarettes and cardiovascular effects suggest a negative effect [18]; however, in general, e-cigarettes are considered less harmful than traditional smoking [19].

One randomized controlled trial found that after 1-month, endothelial function and vascular stiffness improved significantly in participants who switched from smoking to using e-cigarettes compared with those who continued to smoke. The improvement was larger if participants switched to e-cigarettes completely and very similar for nicotine-containing and nicotine-free e-cigarettes [20]. Our own work on e-cigarettes’ short-term, physiological effects suggests that positive indications appear earlier in the smoking cessation time-line, and that they are similar to those offered by NRT [21]. Nevertheless, to date, no evidence has been published on the stability of improvements over time, particularly in comparison to NRT, and the range of outcome measures has been limited.

The present study therefore aimed to compare medium- (3 months) and longer-term (6 months) cardiovascular effects in smokers who attempted to quit smoking using behavioral support and (a) e-cigarettes with nicotine, (b) e-cigarettes without nicotine, and (c) prescription NRT.

Methods
The full protocol, alongside sample size calculations, has been published previously [22].

Design and setting
This single-center pragmatic three-arm randomized controlled trial was conducted in Sheffield, UK; recruitment took place between June 2017 and July 2019.

Participant recruitment
Participants were recruited from the community [22]. Eligible were smokers who had smoked ≥ 10 cigarettes per day for the last year, were aged ≥ 18, and willing to make a cessation attempt using a stop-smoking service or e-cigarettes.

Exclusion criteria were (i) inability to walk; (ii) recent (within 6 months) CVD events or cardiac surgery; (iii) insulin-controlled diabetes mellitus; (iv) coexisting skin conditions, leg ulcers, vasculitis, or deep venous occlusion; (v) pregnancy; (vi) major surgery scheduled during the study; (vii) contraindications /unsuitability for NRT; (viii) current daily use of e-cigarettes; and (ix) current cessation attempt supported by a stop-smoking service.

Procedures
Following a telephone pre-screening and information about study procedures, participants were invited to Sheffield Hallam University to provide informed consent and undertake baseline assessments. They were enrolled by a researcher not involved in group allocation, intervention delivery, or assessments. Following baseline, participants were randomized remotely into three groups by an independent statistician using a computer-generated (nQuery Advisor 6.0, Statistical Solutions, Ireland) block-randomization stratified by gender and “pack-years” (number of packs (20 cigarettes per pack) per day times number of years smoked). The study statistician allocated
a unique trial number to each participant for the study duration. Outcome assessors were blinded to group allocation and participants were reminded regularly not to share their group allocation with assessors or those providing behavioral support. The study statistician/health economist was blinded to group allocation. Those delivering the intervention were only blinded in relation to which e-cigarette group the participants belonged to as the NRT group was receiving support through the stop-smoking service. No blinding existed for participants, as NRT was delivered separately and as experienced users of nicotine, the e-cigarette groups were able to determine the presence or absence of nicotine. During their initial behavioral support sessions, participants set a “quit date” to stop smoking completely. This defined timing of follow-up visits.

Intervention

**Nicotine-containing e-cigarettes group and nicotine-free e-cigarettes group**

Behavioral support was offered for a 3-month period through the research team. This was necessary as e-cigarettes were not part of the treatments offered by the local stop-smoking services at the time of the study. Both groups received complimentary e-cigarette equipment and refills (Tornado V5, Totally Wicked, Blackburn, UK), together with instructions on correct usage. Participants, on average, received 20 bottles of 10 ml during the intervention period. The nicotine-containing e-cigarette group received liquids with nicotine strength of up to 18 mg/ml, the nicotine-free e-cigarette group received nicotine-free liquids (0 mg/ml). Participants could choose ice menthol or tobacco flavor (Red Label, Totally Wicked, Blackburn, UK).

**Prescription NRT group** Following allocation, participants were referred to Sheffield stop-smoking services for behavioral support for three months. They received money or shopping vouchers (depending on personal preference) as reimbursement for NRT prescription charges.

To ensure comparability of behavioral support provided, all groups received the same level and type of behavioral support as currently offered as standard by stop-smoking services, in the form of regular face-to-face or telephone appointments as per relevant guidelines, e.g., minimum of 6 support sessions within the 3-month period [23]. All advisors had completed the same behavioral support training. To support the successful participation of our participants, we used our “six pillars of adherence” framework (based upon “social support,” “education,” “reachability,” “small groups intervention implementation,” “reminders,” and “simplicity”). None of the participants experienced side effects due to their participation in the intervention.

**Measures**

Age, gender, carbon monoxide (CO—to confirm smoking status), body mass index, blood pressure, number of cigarettes and years smoked, and physical activity measured using the SF-IPAQ [24] were recorded at baseline. Body mass index, CO, blood pressure, and physical activity assessments were repeated at 3 and 6-month follow-up.

**Primary outcome**

Macrovascular function was assessed using percentage change in flow-mediated dilation. Smoking is associated with reduced FMD. Reduced altered brachial artery FMD is an early marker for endothelial dysfunction, a CVD risk factor [6], and considered a predictor for long-term, adverse cardiovascular events [25]. FMD is a non-invasive, nitric oxide-mediated measure. Baseline scanning to assess resting vessel diameter was recorded over 3 min, following a 10-min resting period, using a Nemio XG (Toshiba, Tokyo, Japan) ultrasound machine, according to the International Brachial Artery Reactivity Task Force guidelines [26]. Fixed anatomic landmarks (side branches) were used to ensure that the same artery portion was assessed on each occasion. The technical error in our lab for FMD is 5% [26]. FMD is presented as change in post-stimulus diameter as a percentage of the baseline diameter (%FMD).

**Secondary outcomes**

Upper-body microvascular function was assessed using peak cutaneous vascular conductance (CVC) responses to acetylcholine (ACh) and sodium nitroprusside (SNP) as indicators of microvascular endothelial-dependent and endothelial-independent vasodilation, respectively, measured using Laser Doppler Fluximetry and Iontophoresis, using a standardized procedure [27].

Cutaneous red cell flux was measured by placing an iontophoresis laser Doppler probe (PF481-1; Perimed AB), connected to a laser Doppler fluximeter (PF5001; Perimed AB), in the center of each of two drug delivery electrodes ([PF383; Perimed AB, Jarfalla, Sweden] positioned over healthy-looking skin, approximately 4 cm apart with one containing 100 μL of 1% ACh (Miochol-E, Novartis, Stein – endothelium-dependent vasodilator) and the other 100 μl of 1% SNP (Nitroprussiat, Rottapharm – endothelium-independent vasodilator). Measurements of red cell flux (recorded in arbitrary units, AU) were divided by corresponding MAP values (in mmHg) to give CVC in AU/mmHg. Here we present ACh and

...
SNP peak CVC responses. The technical error of measurement for drug-induced peak flux responses in our laboratory is 15% [28].

Mean arterial pressure (MAP) was calculated using the following formula:

\[
\frac{(2 \times \text{Diastolic pressure}) + \text{Systolic pressure}}{3}
\]

MAP was not included in the original list of outcomes as a separate outcome. However, it was decided to be analyzed and presented separately, due to its common use as a surrogate marker for arterial stiffness [28]. All cardiovascular outcomes (following, micro- and macro-vascular assessments) were assessed by the same researcher, at all time-points.

Additional outcome measures include the following: (i) quality of life and health economics; preferences were calculated using EQ-5D-5L Index values and visual analog scale (VAS) scores, and the five discrete EQ-5D dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) were assessed [29]; (ii) Q-Risk to assess risk of CVD; [30] and (iii) “Finger prick” test to calculate the total cholesterol (TC) over high-density lipoprotein (HDL) ratio [31].

All outcomes were assessed with participants abstaining from caffeine, main meals, supplements, and e-cigarettes and smoking for at least 3 h prior to the assessments. Premenopausal women were studied during days 1–7 of their menstrual cycle to minimize the influence of cyclical changes in female hormones and strenuous exercise was avoided for at least 12 h prior to the assessments. Outcomes were assessed at baseline and repeated at 3 and 6 months after the quit date. Resource use (e.g., GP practice and clinic visits) and personal out-of-pocket expenditure (e.g., travel for appointments, prescriptions, and products purchased to quit smoking) were collected via participants’ diaries maintained from baseline to the end of intervention (3 months) period using standard procedures.

Sample
In total, 248 participants were randomized (Fig. 1). Data of four were removed following their withdrawal from the study (1 in the nicotine-containing, 1 in the nicotine-free, 2 in the NRT group). The 3-month follow-up was completed by 207 participants, the 6-month follow-up by 202 participants. Participants were included whether they stopped smoking or not.

Statistical analysis
Data were analyzed in SPSS 24 (IBM U.K. Limited, Hampshire, UK) on an intention-to-treat basis, using the “last observation carried forward” method for those participants that had no data for the 3- and 6-month follow-ups, respectively.

We developed a multiple linear regression model for our repeated continuous outcome measures (%FMD, ACh, SNP, MAP), using a generalized estimating equations (GEE) approach. We made this change from the ANOVA specified in the protocol as GEE is more robust to misspecification of the dependency structure, which results from the repeated assessments of individual over time [32]. GEE used age (in completed years), gender and baseline measurements (or 3-month values for change over 6-month analysis) to control for and predict net-changes in these outcome measures over the 3- and 6-month periods, across our three randomized groups. To explore the interaction between our repeated assessments and our treatment groups, we introduced treatment groups dummy variables, which were assessed over each time-point (i.e., 3 and 6 months), using an established methodology as described in Twisk et al. [33]. Our analysis was also varied against our original protocol, in that we decided against including pack years in the model, due to the excellent balance between groups; age was included instead. A separate analysis using mixed effect models repeat measurement (MMRM) was completed after using multiple imputation for missing values for four outcome variables at 3- and 6- month follow-ups; findings did not differ to those obtained through the GEE modeling.

As additional post hoc analyses, separate GEE models were run for the “cessation” sub-group, which included those that stated that they had stopped smoking and had their status biochemically validated by exhaled air measurement of < 10 ppm CO in line with the Russell Standard [34].

Unadjusted mean differences (d) were calculated as the mean change from baseline to a given time point, for the %FMD, ACh, SNP, and MAP.

For health-related quality of life (HRQoL), mean values for the three participant groups were compared, and the net changes from baseline to 3 and 6 months were estimated. Also, the proportion of patients with sub-optimal levels (i.e., levels 2–5) on each of the five dimensions was compared at baseline, 3, and 6 months. Quality-adjusted life-years (QALYs) were calculated by multiplying the duration of time spent in various health states by the HRQoL weight (i.e., utility score) associated with that health state. A similar approach (i.e., paired t-tests used to compare differences in means at two points in time (3 and 6 months over baseline values) across three quit-smoking groups) was chosen for the other secondary
outcomes, including Q-Risk and the total cholesterol (TC) over high-density lipoprotein (HDL) ratio.

Health economics were assessed using participants’ resource use diaries alongside costs for the delivery of 12 weeks of behavioral change intervention (researcher’s time, room hire charges, and travel expenses), and costs for the intervention materials (electronic cigarette, adapter, atomizer & liquids). NHS smoking cessation delivery costs were estimated to include clinic nurse time and the number of sessions delivered to NRT participants. Participants’ use of NHS services was priced using 2020 PSSRU costings or Department of Health reference costs [35].

Role of the funding source
The trial was funded by Heart Research UK under a Translational Research Grant (RG2658). The funder had no role in the study’s design, conduct, and reporting.

Results
Participants
Baseline characteristics are presented in Table 1.
Primary outcome: macrovascular assessment

Compared to baseline, %FMD was improved at both 3- and 6-month follow-ups in all three groups. There was an improvement in %FMD at 3 months (β = 3.33; 95% CI: 2.61 to 4.05, \( p < 0.0001 \)) and at 6 months (β = 2.69; 95% CI: 2.02 to 3.35, \( p < 0.0001 \)). There was no statistically significant difference in %FMD between the interventions (Table 2). Age did not appear to affect our findings, although gender did, as females had a greater gain in macrovascular function improvement than males (β = −1.32, 95% CI: −2.24 to −0.4, \( p = 0.005 \)). There was also a significant combined effect of group and follow-up visits (β = 3.17, 95% CI: 1.37 to 3.59; \( p = 0.001 \)).

Unadjusted mean differences from baseline (\( d \)) were high for all groups both at 3 (\( d = 4.14 \), 95% CI: 2.57 to 5.51, \( p < 0.001 \)) for the nicotine-free e-cigarette group, \( d = 3.50 \), 95% CI: 2.28 to 4.72 for the nicotine-containing e-cigarette group, \( d = 2.36 \), 95% CI: 1.17 to 3.56, \( p < 0.001 \), for the NRT group) and 6 months (\( d = 2.48 \), 95% CI: 1.35 to 3.62 for the nicotine-free e-cigarette group, \( d = 2.78 \), 95% CI: 1.66 to 3.90, \( p < 0.001 \) for the nicotine-containing e-cigarette group, \( d = 2.79 \), 95% CI: 1.52 to 4.06 for the NRT group).

Secondary outcomes: microvascular assessment

Acetylcholine (ACh)

Similar to %FMD, CVC values for ACh improved significantly over baseline in all three groups both at 3 and 6 months. There was an improvement at 3 (β = 0.2, 95% CI: 0.01 to 0.4, \( p = 0.04 \)) and 6 months (β = 0.27, 95% CI: 0.09 to 0.45, \( p = 0.004 \)). There were no statistically significant differences between groups at follow-up (Table 2). Neither age nor gender affected the outcome in endothelial-dependent microvascular vasodilation (Table 2; Fig. 2 Central Illustration Graph B). Nevertheless, the combination of group and follow-up visits did (β = 0.32, 95% CI: 0.23 to 0.4; \( p = 0.03 \)).

Unadjusted d values were high, particularly at 6 months (\( d = 0.19 \), 95% CI: −0.08 to 0.41, \( p = 0.29 \) for the nicotine-free e-cigarette group, \( d = 0.30 \), 95% CI: −0.01 to 0.61, \( p = 0.04 \) for the Nicotine-containing e-cigarette group, \( d = 0.41 \), 95% CI: 0.08 to 0.74, \( p = 0.02 \) for the NRT group).
Sodium nitroprusside (SNP)

As with the previous outcomes, SNP improved over baseline, at both follow-up visits. There was an improvement at both 3 (β = 0.26, 95% CI: 0.09 to 0.42, \( p = 0.001 \)) and 6 months (β = 0.28, 95% CI: 0.11 to 0.45, \( p = 0.002 \)), with the combination of group and visit bearing an effect to the outcome (β = 0.49, 95% CI: 0.15 to 0.67, \( p = 0.002 \)). There were no significant differences between groups (Table 2; Fig. 2 Central Illustration Graph C) and neither age nor gender significantly affected this outcome.

The positive improvement trend observed in other outcomes was also observed for SNP in unadjusted d as well, particularly at the 6-month follow-up: (d = 0.40, 95% CI: 0.13 to 0.65, \( p = 0.004 \) for the nicotine-free e-cigarette group, \( d = 0.22, 95\% \text{ CI: } -0.08 \text{ to } 0.52, \ p = 0.14 \) for the nicotine-containing e-cigarette group, \( d = 0.21, 95\% \text{ CI: } -0.55 \text{ to } 0.12, \ p = 0.21 \) for the NRT group).

Mean arterial pressure (MAP)

MAP readings were reduced in all three intervention groups at both follow-ups (β = −1.74, 95% CI: −2.57
to $-0.91; p=0.001$ and $\beta=-1.41, 95\% \text{ CI: } -2.31 \text{ to } -0.51; p=0.002$). There were no statistically significant differences between groups (Table 2, Fig. 2 Central Illustration Graph D) and no combined effect of group and follow-up visit ($\beta=0.26, 95\% \text{ CI: } -1.22 \text{ to } 1.74; p=0.73$). The reduction was affected by gender ($\beta=4.33, 95\% \text{ CI: } 1.86 \text{ to } 6.79; p=0.001$) and age ($\beta=0.23, 95\% \text{ CI: } 0.14 \text{ to } 0.33; p=0.001$), with females and lower age groups benefiting the most.

As with the other measures, unadjusted $d$ values suggest an improvement particularly at 6 months ($d=-0.26, 95\% \text{ CI: } -1.24 \text{ to } 1.79, p=0.53$ for the nicotine-free e-cigarette group, $d=-2.23, 95\% \text{ CI: } -3.74 \text{ to } -0.71, p=0.004$ for the nicotine-containing e-cigarette group, $d=-2.18, 95\% \text{ CI: } -3.86 \text{ to } -0.49, p=0.01$ for the NRT group).

**Cessation subgroup**

In the nicotine-containing e-cigarette group, 39 successfully stopped smoking at 3 and 36 at 6 months. In the nicotine-free e-cigarette group, it was 34 and 30 at 3 and 6 months, respectively; and in the NRT group 33 and 25 at 3 and 6 months respectively. The post hoc subgroup analysis showed strong effects for %FMD at both follow-up sessions ($\beta=2.40, 95\% \text{ CI: } 1.66 \text{ to } 3.14; p<0.0001$ for 3 months and $\beta=2.99, 95\% \text{ CI: } 2.22 \text{ to } 3.77; p<0.0001$ for 6 months). No differences were observed between groups at both time-points (Table 3).

Unadjusted mean differences from baseline ($d$) were high for all groups both at 3 (e.g., $d=4.78, 95\% \text{ CI: } 2.27 \text{ to } 7.29, p<0.0001$ for the nicotine-free e-cigarette group) and 6 months (e.g., $d=4.40, 95\% \text{ CI: } 2.14 \text{ to } 6.66, p=0.001$ for the NRT group) (Table 3).

**Secondary outcomes: other measures**

For Quality of life, post-quit improvements were observed in QALYs, both in % and actual values [e.g., $F=4.17, p=0.02, df=2,243$ at 3 and $F=5.03, p=0.01, df=2,243$ at 6 months respectively for QALY (%)]. Improvements were also detected for pain (%) ($F=3.43, p=0.03, df=2,243$ at 3 months) and depression and anxiety (%) ($F=4.54, p=0.01, df=2,243$ at 3 and $F=6.25, p=0.01, df=2,243$ at 6 months).
| Variables                        | Group/follow-up                                                                 | B-coeff | Exp (B) | 95% CI       | p value |
|---------------------------------|---------------------------------------------------------------------------------|---------|---------|--------------|---------|
|                                 |                                                                                 |         |         | Lower        |         | Upper   |         |
| %FMD                            |                                                                                 |         |         |              |         |         |         |
| Group                           | NRT over EC nicotine-containing                                                | 0.46    | 1.61    | −0.59        | 1.54    | 0.38    |         |
|                                 | EC nicotine-free over EC nicotine-containing                                    | −0.57   | 0.57    | −1.74        | 0.60    | 0.34    |         |
| Follow-up                       | 3 m over baseline                                                               | 2.40    | 20.04   | 1.66         | 3.14    | <0.0001 |         |
|                                 | 6 m over baseline                                                               | 2.99    | 11.04   | 2.22         | 3.77    | <0.0001 |         |
| Gender                          | Male over female                                                                | −1.35   | 0.26    | −2.27        | −0.43   | 0.004   |         |
| Age                             | −0.02                                                                          | 0.98    |         | −0.05        | 0.01    | 0.27    |         |
| Intercept                       |                                                                                 | 7.67    | 5.92    | 9.42         | <0.0001 |         |         |
| %FMD changes over baseline      |                                                                                 |         |         |              |         |         |         |
|                                 | NRT                                                                             |         |         |              |         |         |         |
|                                 | 95% CI                                                                          |         |         |              |         |         |         |
|                                 | Upper                                                                           |         |         |              |         |         |         |
|                                 | p value                                                                         |         |         |              |         |         |         |
|                                 | Mean difference                                                                 |         |         | Mean difference | 95% CI | p value |
|                                 | Lower                                                                          |         |         | Lower        |         |         |         |
|                                 | 3 months over baseline                                                          | 2.61    | 0.97    | 4.25         | 0.003   |         |         |
|                                 | Cessation subgroup                                                              | 3.94    | 1.73    | 6.15         | 0.001   |         |         |
|                                 | 6 months over baseline                                                          | 4.40    | 2.18    | 6.66         | 0.001   |         |         |
|                                 | Cessation subgroup                                                              | 2.96    | 1.17    | 4.74         | 0.002   |         |         |
|                                 | EC—nicotine-free                                                                | 4.78    | 2.27    | 7.29         | 0.001   |         |         |
|                                 | Mean difference                                                                 | 2.97    | 0.90    | 5.04         | 0.006   |         |         |

%FMD, percentage change in flow-mediated dilation
at 6 months respectively. No changes were detected in mobility (%), movement (%), self-care (%) or the participants’ self-rated health (VAS) (Table 4).

Reductions were observed for Q-Risk at 3 and 6 months for all three groups with the exception of the Q-risk % at 6 months for NRT. No statistically significant changes were observed for TC/HDL Ratio (Table 5).

Our health economics’ assessment suggests a lower per-participant cost for e-cigarettes (nicotine-containing = £192.55, nicotine-free = £177.63) in comparison to NRT (£246.92), due to a higher resource-use cost observed in the NRT group (Please see Online Supplement).

**Discussion**

Participants improved their cardiovascular health prospects, irrespective of whether they used NRT or e-cigarettes with or without nicotine. These improvements appear both overall and in those that quit successfully. Most of our findings (driven by the improvements in those that quit successfully, as our sub-group analysis shows) suggest endothelial function improvements, which appear quite early in the smoking cessation timeline [21], continue to exist in both smaller and larger conduits, at least up to 6 months after smokers quit. This potentially happens via a reduction in the production of oxidative stress and ultimately an increase of NO bioavailability, an imbalance between which is known to be created via smoking [36]. ACh is an endothelial-dependent vasodilator primarily associated with an increase in NO bioavailability, particularly at higher ACh doses [27]. Additionally, endothelium-derived NO is considered as a principal FMD mediator [26], although this view is debated [27].

Considering that SNP is a direct NO donor [27], our findings suggest that smoking cessation offers further NO-bioavailability benefits through an improvement in smooth muscle cell vascular function, as the observed

---

### Table 4  Quality of life by domain at baseline, 3 and 6 months follow-ups of all participants

|                     | Nicotine replacement therapy | Nicotine-containing e-cigarettes | Nicotine-free e-cigarettes | F value, p value, and degrees of freedom |
|---------------------|------------------------------|---------------------------------|---------------------------|-----------------------------------------|
| **Mobility (%)**    |                              |                                 |                           |                                         |
| Baseline            | 9.88                         | 15.48                           | 13.92                     | F = 0.60, p = 0.55, df = 2,243        |
| 3 months            | 7.41                         | 9.52                            | 10.13                     | F = 0.20, p = 0.82, df = 2,243        |
| 6 months            | 6.17                         | 7.14                            | 8.86                      | F = 0.21, p = 0.81, df = 2,243        |
| **Self-care (%)**   |                              |                                 |                           |                                         |
| Baseline            | 2.47                         | 5.95                            | 3.80                      | F = 0.65, p = 0.52, df = 2,243        |
| 3 months            | 2.47                         | 2.38                            | 1.27                      | F = 0.12, p = 0.84, df = 2,243        |
| 6 months            | 1.23                         | 3.57                            | 2.53                      | F = 0.20, p = 0.82, df = 2,243        |
| **Usual activity (%)** |                             |                                 |                           |                                         |
| Baseline            | 8.64                         | 16.67                           | 18.99                     | F = 1.89, p = 0.15, df = 2,243        |
| 3 months            | 7.41                         | 14.29                           | 12.66                     | F = 1.04, p = 0.36, df = 2,243        |
| 6 months            | 6.17                         | 15.48                           | 10.13                     | F = 1.90, p = 0.15, df = 2,243        |
| **Pain (%)**        |                              |                                 |                           |                                         |
| Baseline            | 35.80                        | 39.29                           | 46.84                     | F = 1.05, p = 0.35, df = 2,243        |
| 3 months            | 23.46                        | 25.00                           | 29.11                     | F = 0.35, p = 0.70, df = 2,243        |
| 6 months            | 17.28                        | 21.43                           | 34.18                     | F = 3.43, p = 0.03, df = 2,243        |
| **Depression/anxiety (%)** |                        |                                 |                           |                                         |
| Baseline            | 38.27                        | 45.24                           | 51.90                     | F = 1.50, p = 0.22, df = 2,243        |
| 3 months            | 23.46                        | 42.86                           | 43.04                     | F = 4.54, p = 0.01, df = 2,243        |
| 6 months            | 24.69                        | 50.00                           | 44.30                     | F = 6.25, p = 0.01, df = 2,243        |
| **QALY (%)**        |                              |                                 |                           |                                         |
| Baseline            | 41.98                        | 34.52                           | 32.91                     | F = 0.81, p = 0.45, df = 2,243        |
| 3 months            | 62.96                        | 44.05                           | 43.04                     | F = 4.17, p = 0.02, df = 2,243        |
| 6 months            | 64.20                        | 42.86                           | 43.04                     | F = 5.03, p = 0.01, df = 2,243        |
| **VAS (Mean, SD)**  |                              |                                 |                           |                                         |
| Baseline, mean (SD) | 71.59 (15.98)                | 67.26 (15.24)                   | 70.96 (17.14)             | F = 1.74, p = 0.18, df = 2,243        |
| 3 months, mean (SD) | 72.38 (14.33)                | 70.91 (14.42)                   | 69.81 (19.24)             | F = 0.51, p = 0.60, df = 2,243        |
| 6 months, mean (SD) | 75.38 (13.80)                | 70.29 (16.12)                   | 72.78 (16.22)             | F = 2.24, p = 0.11, df = 2,243        |
### Table 5 Change of secondary outcome variables over baseline

| Variables—change over baseline | Nicotine replacement therapy (NRT) | Nicotine-containing e-cigarettes | Nicotine-free e-cigarettes |
|-------------------------------|-----------------------------------|---------------------------------|---------------------------|
|                               | Mean difference | 95% CI | p value | Mean difference | 95% CI | p value | Mean difference | 95% CI | p value |
|                               | Lower | Upper |         | Lower | Upper |         | Lower | Upper |         |
| **CO (reduction in parts per million)** |      |       |         |      |       |         |      |       |         |
| 3 months over baseline        | 10    | 8     | 11     | < .001 | 9     | 7     | 11     | < .001 | 7     | 5     | 9     | < .001 |
| 6 months over baseline        | 8     | 6     | 10     | < .001 | 9     | 7     | 11     | < .001 | 6     | 4     | 8     | < .001 |
| **TC/HDL ratio (reduction)**  |      |       |         |      |       |         |      |       |         |      |       |         |      |       |         |
| 3 months over baseline        | 0.89  | −0.16 | 1.91   | 0.09  | 0.18  | −0.02 | 0.39   | 0.08  | 0.11  | −0.14 | 0.36  | 0.39  |
| 6 months over baseline        | 0.78  | −0.27 | 1.80   | 0.15  | 0.23  | 0.06  | 0.40   | 0.009 | 0.01  | −0.23 | 0.24  | 0.97  |
| **QRISK (reduction in %)**    |      |       |         |      |       |         |      |       |         |      |       |         |      |       |         |
| 3 months over baseline        | 1.8   | 0.9   | 2.7    | < .001 | 1.6   | 0.6   | 2.6    | 0.002 | 2.1   | 1.2   | 3.0   | < .001 |
| 6 months over baseline        | 0.9   | −0.4  | 2.3    | 0.164 | 1.8   | 0.8   | 2.7    | < .001 | 1.7   | 0.7   | 2.7   | 0.001 |
improvement in SNP-induced vasodilation suggests. This is a change from our short-term observations, in which we found no improvements from the baseline, in any of our groups [25]. Therefore, it is possible that although e-cigarettes are known to have a negative acute effect on NO-bioavailability and endothelial function of healthy adults [37] or when comparing e-cigarette users with healthy adults [38], they appear to support the reversal of the smoking-induced endothelial dysfunction, in a similar manner to NRT. This happens, however, at a later stage of the smoking cessation process, suggesting that the smooth muscle cell damage, which is caused by cigarettes (possibly via inducing a pro-inflammatory/matrix remodeling phenotype in smooth muscle cells [39]), is more persistent. The slow reversal is a positive sign, which could also reduce the risk of atherosclerosis and stroke [39].

Although the assessment of vascular stiffness is a complex process, and a simple, surrogate measure cannot fully determine whether a change occurs or not, recent work suggests the predictive role of MAP for arterial stiffness [39], with increases in the former suggesting also an increase to the latter [40]. Thus, the observed MAP reduction in all three trial groups may well suggest an improvement in vascular stiffness as well. Direct testing, which was not possible in our study, due to the high participant burden of the assessments that we used, can confirm our findings.

Our findings agree with recent work by George et al. [20], who reported that endothelial function and arterial stiffness in smokers improved within 1 month of switching to e-cigarettes. Our work goes some steps further, showing that endothelial function is markedly improved in small veins and arteries, if smokers continue to abstain, for longer periods, from cigarettes, using NRT as well. This is an important finding, which can be potentially encouraging for those who wish to stop smoking, especially as impaired vascular function—even at pre-clinical groups—is associated with a higher CVD risk [41].

Stronger improvement in vascular stiffness as well. Direct testing, which was not possible in our study, due to the high participant burden of the assessments that we used, can confirm our findings.

Future research
The next step would be to explore outcomes beyond 6 months. It would also be interesting to explore the cardiovascular effects of different devices and liquids, which would be followed if e-cigarettes were widely adopted as a smoking cessation aid, in supported smoking cessation attempts. It enabled comparison with a licensed and widely accepted route for smoking cessation. The success rate of our intervention (which can be attributed to the flexibility of the behavioral support offered, and the intense way that the intervention was delivered), although it cannot be traced for a period longer than 6 months, suggests the need of healthcare investment in these services. Finally, the inclusion of micro-circulation outcomes is another strength as pathological changes in the microcirculation mirror changes in arteries, making it an appropriate area to study to achieve early detection.

Conclusions
Smokers attempting to quit experienced a positive cardiovascular impact after both a 3- and 6-month period. None of the groups (i.e., nicotine-containing and nicotine-free e-cigarettes or NRT) offered superior cardiovascular benefits to the others.

Abbreviations
ACh: Acetylcholine; BMI: Body mass index; CVC: Cutaneous vascular conductance; CVD: Cardiovascular disease; E-cigarettes: Electronic cigarettes; FMD:
Flow-mediated dilation; MAP: Mean arterial pressure; NRT: Nicotine replacement therapy; SNP: Sodium nitroprusside.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02451-9.

**Acknowledgements**
We would like to thank our participants for taking part in our study and the SSSs in Sheffield for accepting referrals and supporting our participants in our NRT-based group.

We would like also to thank Dr G. Jones, Mrs S. Kesterton, Miss H. Leahy, Miss J. Stockton and Mr A. Bugg for supporting the study procedures, at different stages. Finally, we would like to thank Dr Kevin Lewis, a true smoking cessation pioneer in the UK, for his strong encouragement to carry out this work.

**Authors’ contributions**
MK designed the study, oversaw implementation and drafted the initial manuscript. AG contributed to study design and conducted statistical and health economics’ analyses. LSB supported the literature search, contributed to the study design, and critically reviewed and revised the manuscript. EM undertook data collection and helped draft the manuscript. All authors were responsible for draft revisions and have read and agreed to the published version of the manuscript. The authors declare that the manuscript has not been published or submitted for publication elsewhere.

**Funding**
This study was supported by a Translational grant (RG2658) from Heart Yorkshire and Humber NHS Research Ethics Committee, which confirmed that it did not require NHS Research Ethics Committee approval nor was a Clinical Trial of an Investigational Medicinal Product as defined by the EU Directive 2001/20/EC. All participants provided informed consent prior to their participation in the study.

**Ethics approval and consent to participate**
The Ethics Committee of the Faculty of Health and Wellbeing of Sheffield Hallam University approved the study (HWB-2016-17-SE-10). It was assessed by the UK Medicines and Healthcare products Regulatory Agency and the Yorkshire and Humber NHS Research Ethics Committee, which confirmed that it did not require NHS Research Ethics Committee approval nor was a Clinical Trial of an Investigational Medicinal Product as defined by the EU Directive 2001/20/EC. All participants provided informed consent prior to their participation in the study.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1. Lifestyle Exercise and Nutrition Improvement (LENI) Research Group, Department of Nursing and Midwifery, Sheffield Hallam University, Sheffield S10 2BP, UK. 2. Centre for Sport and Exercise Science, Sheffield Hallam University, Sheffield S10 2BP, UK. 3. Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK. 4. SPECTRUM Research Consortium, Edinburgh, UK.

**Received:** 14 January 2022  **Accepted:** 27 June 2022  **Published online:** 16 August 2022

**References**
1. GBD Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017. https://doi.org/10.1016/S0140-6736(17)30819-X.
2. Office for National Statistics. Adult smoking habits in the UK: 2019. 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthanddifeexpectancies/bulletins/adultsmokinghabits/ingreatbritain/2019.
3. NHLS Digital. Statistics on Smoking England 2018. 2018. https://files.digital.nhs.uk/0C/95F481/stat-smok-eng-2018-rep.pdf.
4. Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Centers for Disease Control and Prevention (US). 2010.
5. Office on Smoking and Health (US). The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Publications and Reports of the Surgeon General. 2006.
6. U.S. Department of Health and Human Services. Smoking Cessation: A Report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2020.
7. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016. https://doi.org/10.1002/14651858.CD009826.pub.
8. Hartmann-Boyce J, Hong B, Livingstone-Banks J, Wheat H, Fanshawe TR. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD009670.pub.
9. Brose LS, West R, McDermott MS, Fidler JA, Croghan E, McEwen A. What makes for an effective stop-smoking service? Thorax. 2011;66(10):924–6. https://doi.org/10.1136/thoraxjnl-2011-200251.
10. Jackson SE, McGowan JA, Ubbi HK, et al. Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation. Addiction. 2019. https://doi.org/10.1111/add.14549.
11. Action on Smoking and Health (ASH) and Cancer Research UK (CRUK). Many Ways Forward: Stop smoking services and tobacco control work in English local authorities. 2020. https://ash.org.uk/wp-content/uploads/2020/01/Many-Ways-Forward.pdf.
12. McNeill A, Brose LS, Calder R, Simonavicius E, Robson D. Vaping in England: an evidence update including vaping for smoking cessation, 2019. A report commissioned by Public Health England. Public Health England. 2021.
13. Hartmann-Boyce J, McBinnie H, Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2021. https://doi.org/10.1002/14651858.CD010216.pub.
14. Jackson SE, Kotz D, West R, Brown J. Moderators of real-world effectiveness of smoking cessation aids: a population study. Addiction. 2019. https://doi.org/10.1111/add.14656.
15. Beard E, West R, Mitchl S, Brown J. Association of prevalence of electronic cigarette use with smoking cessation and cigarette consumption in England: a time-series analysis between, 2006 and 2017. Addiction. 2020. https://doi.org/10.1111/add.14851.
16. MacDonald A, Middledorf HR. Electronic cigarettes and cardiovascular health: what do we know so far? Vasc Health Risk Manag. 2019;15:159–74.
17. Taran R, Barr RG, Benowitz NL, et al. E-Cigarettes and Cardiopulmonary Health Function (Oxf). 2021. https://doi.org/10.1093/jpmed/zaab604.
18. Kennedy CD, van Schalkwyk MCL, Mcke M, Psinger C. The cardiovascular effects of electronic cigarettes: A systematic review of experimental studies. Prev Med. 2019. https://doi.org/10.1016/j.ypmed.2019.105770.
19. Benowitz NL, Fraiman JB. Cardiovascular effects of electronic cigarettes. Nat Rev Cardiol. 2017. https://doi.org/10.1038/nrcardio.2017.36.
20. George J, Hussain M, Vadiveloo T, et al. Cardiovascular Effects of Switching From Tobacco Cigarettes to Electronic Cigarettes. J Am Coll Cardiol. 2019. https://doi.org/10.1016/j.jacc.2019.09.067.
21. Klonizakis M, Gumber A, McIntosh E, Brose LS. Short-Term Cardiovascular Effects of E-Cigarettes in Adults Making a Stop-Smoking Attempt: A

**Additional file 1.**

- Additional file 1. 
- Klonizakis K, Bevan J, Gumber A, et al. Short-term cardiovascular effects of electronic cigarettes in adults making a stop-smoking attempt: a randomised controlled trial. Lancet. 2022.
- Supplementary Information
- Ethical approval: The study was conducted in accordance with the Declaration of Helsinki (2013) and was approved by the Ethics Committee of the Faculty of Health and Wellbeing of Sheffield Hallam University (HWB-2016-17-SE-10). All participants provided informed consent prior to their participation in the study.
- Consent for publication: Not applicable.
- Competing interests: The authors declare that they have no competing interests.
22. Klonizakis M, Crank H, Gumber A, Brose LS. Smokers making a quit attempt using e-cigarettes with or without nicotine or prescription nicotine replacement therapy: Impact on cardiovascular function (ISME-NRT) - a study protocol. BMC Public Health. 2017. https://doi.org/10.1186/s12889-017-4206-y.

23. The National Centre for Smoking Cessation and Training (NCSCT). Standard Treatment Programme - A guide to providing behavioural support for smoking cessation. NCSCT, http://www.ncscct.co.uk/usr/pub/NCSC%20STP.pdf. 2014.

24. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. MSSE. 2003. https://doi.org/10.1249/01.MSS.0000078924.61453.FB.

25. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014. https://doi.org/10.1161/ATVBAHA.113.300156.

26. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002. https://doi.org/10.1016/s0735-1097(01)01746-6.

27. Klonizakis M, WINTER E. Effects of arm-cranking exercise in cutaneous microcirculation in older, sedentary people. Microvas Res. 2011. https://doi.org/10.1016/j.mvr.2011.01.008.

28. Tew GA, Gumber A, McIntosh E, et al. Effects of supervised exercise training on lower-limb cutaneous microvascular reactivity in adults with venous ulcers. Eur J Appl Physiol. 2018. https://doi.org/10.1007/s00421-017-3772-0.

29. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the EQ-5D-5L. Med Care. 2011. https://doi.org/10.1097/01.mlr.0000360799.09417.1f.

30. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ. 2009. https://doi.org/10.1136/bmj.b2584.

31. Maeda K, Noguchi Y, Fuku T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med. 2003. https://doi.org/10.1016/s0091-7435(03)00110-5.

32. Kang H. The prevention and handling of the missing data. Korean J Anesth. 2013. https://doi.org/10.4097/kjae.2013.64.5.402.

33. TWISK J, BOSMAN L, HOEKSTRA T, RIJNHART J, WELTEN M, HEYMANS M. Different ways to estimate treatment effects in randomised controlled trials. Contemp Clin Trials Commun. 2018. https://doi.org/10.1016/j.cctc.2018.03.008.

34. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005. https://doi.org/10.1111/j.1360-0443.2004.00995.x.

35. Curtis LA, Burns A. Unit Costs of Health & Social Care 2020. Personal Social Services Research Unit, University of Kent Canterbury, UK. 2020. 185 pp. ISBN 978-1-911353-12-6

36. Fetterman JL, Keith RJ, Palmisano JN, et al. Alterations in Vascular Function Associated With the Use of Combustible and Electronic Cigarettes. J Am Heart Assoc. 2020.9(9): e014570. https://doi.org/10.1161/JAHA.119.014570.

37. Starker RM, Ali MA, Jabbour PM, et al. Cigarette smoke modulates vascular smooth muscle phenotype: implications for carotid and cerebrovascular disease. PLoS ONE. 2013. https://doi.org/10.1371/journal.pone.0071954.

38. Quinn U, Tomlinson LA, Cockett KR, et al. Nicotine and oxidative stress in smokers: A systematic review and meta-analysis. JSS. Cardiovasc Dis. 2012. https://doi.org/10.1258/cvd.2012.012024.

39. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009. https://doi.org/10.1161/CIRCULATIONAHA.109.864801.

40. Quinn U, Tomlinson LA, Cockett KR, et al. Nicotine and oxidative stress in smokers: A systematic review and meta-analysis. JSS. Cardiovasc Dis. 2012. https://doi.org/10.1258/cvd.2012.012024.

41. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009. https://doi.org/10.1161/CIRCULATIONAHA.109.864801.